Amneal Pharmaceuticals

AMRX · NASDAQ

$19.84+$0.48 (+2.48%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $19.36

Latest news

Press releaseAug 19, 8:00 AM ETBusiness Wire
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
Press releaseAug 10, 8:00 AM ETGlobe Newswire
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
NewsJul 30, 6:00 AM ET
Amneal Pharmaceuticals Q2 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $796.197M Beat $768.206M Estimate
Press releaseJul 30, 6:00 AM ETGlobe Newswire
Amneal Reports Second Quarter 2026 Financial Results
NewsJul 24, 6:25 AM ETStjepan Kalinic
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
Press releaseJul 23, 1:27 PM ETBusiness Wire
Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm
NewsJun 30, 10:17 AM ETVandana Singh
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
NewsJun 29, 3:11 AM ET
Zambon And Amneal's Hopledo Receives Positive CHMP Opinion For Parkinson's Disease, European Launch Expected From October 2026
Press releaseJun 29, 3:00 AM ETGlobe Newswire
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
NewsJun 16, 8:50 AM ET
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose
Press releaseJun 10, 10:09 AM ETPRNewswire
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Press releaseMay 7, 4:01 PM ETGlobe Newswire
Amneal Reports First Quarter 2026 Financial Results
NewsMay 1, 7:11 AM ET
Earnings Scheduled For May 1, 2026
NewsApr 22, 7:15 AM ETNabaparna Bhattacharya
Why Is Amneal Pharmaceuticals Stock Gaining Today?
Press releaseApr 22, 6:17 AM ETBusiness Wire
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
NewsApr 22, 6:06 AM ET
Amneal Pharmaceuticals To Acquire Kashiv BioSciences For $375M In Cash, $375M In Shares Payable Upon Closing And Up To $350M In Potential Payments, Also Reports Preliminary Q1 Sales $723M, Up 4% Yoy, Raises FY2026 Adjusted EPS And Adjusted EBITDA Guidance
Press releaseApr 22, 6:00 AM ETGlobe Newswire
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
NewsApr 16, 11:37 AM ET
FDA Takes Step Forward on Testosterone Therapy for Men
NewsFeb 27, 9:17 AM ETVandana Singh
Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million
NewsFeb 27, 6:11 AM ET
Earnings Scheduled For February 27, 2026
NewsFeb 27, 6:02 AM ET
Amneal Pharmaceuticals Q4 Earnings Summary & Key Takeaways
NewsFeb 26, 9:01 AM ET
Earnings Outlook For Amneal Pharmaceuticals
Press releaseFeb 13, 11:26 AM ETPRNewswire
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
Press releaseJan 27, 6:02 PM ETPRNewswire
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
Press releaseJan 9, 11:00 AM ETBusiness Wire
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease
NewsOct 9, 9:31 AM ETVandana Singh
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
Press releaseOct 6, 8:00 AM ETBusiness Wire
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
NewsSep 26, 8:05 AM ET
Amneal Pharma Submits BLA To FDA For Proposed Biosimilar To XOLAIR, Developed By Kashiv BioSciences
Press releaseSep 26, 8:00 AM ETGlobe Newswire
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
NewsAug 5, 4:32 AM ET
Earnings Scheduled For August 5, 2025
NewsJul 10, 1:49 PM ET
NY State Attorney General Letetia James Posts On X "My office and a coalition of AGs secured $720 million from eight pharmaceutical companies for their roles in fueling the opioid epidemic across our nation. We've now secured over $3 billion for New York that will be used to help prevent future devastation from opioids."
Press releaseMay 2, 6:00 AM ETBusiness Wire
Amneal Reports First Quarter 2025 Financial Results
NewsMay 1, 11:02 AM ET
Examining the Future: Amneal Pharmaceuticals's Earnings Outlook
Press releaseApr 11, 8:00 AM ETBusiness Wire
Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month
Press releaseApr 8, 4:05 PM ETBusiness Wire
Amneal to Report First Quarter 2025 Results on May 2, 2025
Press releaseApr 7, 8:00 AM ETBusiness Wire
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease
Press releaseApr 3, 8:00 AM ETBusiness Wire
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.
Press releaseApr 1, 8:00 AM ETBusiness Wire
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
Press releaseMar 10, 4:05 PM ETBusiness Wire
Amneal to Participate at Upcoming Investor Conference
Press releaseMar 3, 4:05 PM ETBusiness Wire
Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
Press releaseFeb 28, 6:00 AM ETBusiness Wire
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results
Press releaseFeb 19, 8:00 AM ETBusiness Wire
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
Press releaseJan 29, 8:30 AM ETBusiness Wire
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Amneal Pharmaceuticals Q2 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $796.197M Beat $768.206M Estimate

Amneal Reports Second Quarter 2026 Financial Results

Two Years to Build or Pay 200% — Which US Pharma Stocks Win?

Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm

Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness

Zambon And Amneal's Hopledo Receives Positive CHMP Opinion For Parkinson's Disease, European Launch Expected From October 2026

Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations

FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal Reports First Quarter 2026 Financial Results

Earnings Scheduled For May 1, 2026

Why Is Amneal Pharmaceuticals Stock Gaining Today?

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

Amneal Pharmaceuticals To Acquire Kashiv BioSciences For $375M In Cash, $375M In Shares Payable Upon Closing And Up To $350M In Potential Payments, Also Reports Preliminary Q1 Sales $723M, Up 4% Yoy, Raises FY2026 Adjusted EPS And Adjusted EBITDA Guidance

Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

FDA Takes Step Forward on Testosterone Therapy for Men

Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million

Earnings Scheduled For February 27, 2026

Amneal Pharmaceuticals Q4 Earnings Summary & Key Takeaways

Earnings Outlook For Amneal Pharmaceuticals

Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market

TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

Amneal Pharma Submits BLA To FDA For Proposed Biosimilar To XOLAIR, Developed By Kashiv BioSciences

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

Earnings Scheduled For August 5, 2025

Amneal Reports First Quarter 2025 Financial Results

Examining the Future: Amneal Pharmaceuticals's Earnings Outlook

Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

Amneal to Report First Quarter 2025 Results on May 2, 2025

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Amneal to Participate at Upcoming Investor Conference

Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025